<a id="article1.body1.sec3.p4" name="article1.body1.sec3.p4"></a><p>The HAI response (data not shown) was weaker than the neutralising response with seroprotective HAI titres induced in 35% and 60% of subjects respectively for the A/Anhui/1/2005 and A/turkey/Turkey/1/2005 strains following the second dose. Only one subject in the non-adjuvanted group had a seroprotective HAI titre against the A/turkey/Turkey/1/2005 strain.</p>
</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>We have shown that the candidate clade 1 H5N1 inactivated split-virion vaccine adjuvanted with an oil-in-water based emulsion adjuvant system can induce neutralising antibodies against recombinant strains derived from three recently emergent clade 2 viruses belonging to different subclades. Furthermore, this cross-clade immunity was induced at a low HA dose of 3.8 µg. These results are encouraging, as they demonstrate that a vaccine based on an existing H5N1 strain could potentially protect against a range of different emerging H5N1 strains. This is the concept on which the pre-pandemic immunisation strategy is based.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>To be optimal for use in a pre-pandemic immunisation strategy, we need vaccines that i) are safe, ii) are highly immunogenic, iii) exhibit broad cross-immunity and iv) have long- lived immunity. As with other split-virion or whole-virion H5N1 vaccines based on strains derived by reverse genetics <a href="#pone.0001665-Treanor1">[19]</a>–<a href="#pone.0001665-Hehme1">[22]</a>, the candidate adjuvanted vaccine derived from the 2004 H5N1 isolate A/Vietnam/1194/2004 seems to be well tolerated with an acceptable safety profile <a href="#pone.0001665-LerouxRoels1">[23]</a>. The adjuvanted vaccine was also shown to be highly immunogenic, a dose of 3.8 µg HA was sufficient to achieve immunity against the vaccine strain at a level that was acceptable for licensing in US and Europe <a href="#pone.0001665-LerouxRoels1">[23]</a>. An inactivated split-virion H5N1 vaccine has been licensed by the FDA, however this vaccine, which is administered without adjuvant is poorly immunogenic <a href="#pone.0001665-Treanor1">[19]</a>, <a href="#pone.0001665-US2">[25]</a>. Two 90 µg doses are needed to achieve the level of immunity required for licensing compared to one dose of 15 µg for conventional seasonal split-virion vaccines. Adjuvantation with aluminium was shown to only modestly improve the immunogenicity of inactivated split-virion H5N1 vaccine <a href="#pone.0001665-Bresson1">[20]</a> although more promising results were achieved with whole-virion H5N1 vaccines administered with aluminium <a href="#pone.0001665-Lin1">[21]</a>, <a href="#pone.0001665-Hehme1">[22]</a>.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>As previously reported <a href="#pone.0001665-LerouxRoels1">[23]</a>, after 2 administrations of 3.8 µg HA of the AS adjuvanted rH5N1 vaccine, 84% of the 50 volunteers presented seroprotective HAI titres against A/Vietnam/1194/2004 vaccine strain and 86% presented a four-fold seroconversion rate for neutralising antibodies while in the group of volunteers administered with the non-adjuvanted vaccine these percentages were 4% and 22%, respectively <a href="#pone.0001665-LerouxRoels1">[23]</a>.</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4"></a><p>In this report we now provide evidence that the adjuvanted clade 1 candidate vaccine exhibits a broad cross-immunity against circulating strains shown to be responsible for human cases <a href="#pone.0001665-WHO.3">[18]</a>. The effect of the oil-in-water emulsion based adjuvant system in promoting this cross-immunity was contrasting with the absence of a response in the non-adjuvanted group. We demonstrated that, in addition to the recombinant subclade 2.1 A/Indonesia/5/2005 strain, the vaccine also induced neutralising antibodies against two other recombinant strains derived from the recent drift H5N1 strains A/turkey/Turkey/1/2005 and A/Anhui/1/2005 which are, as defined by WHO, representatives of subclades 2.2 and 2.3 respectively. The ability of the vaccine to induce immunity against these three phylogenetic subclades is of relevance as, together with clade 1, they account for the majority of recent circulating H5N1 isolates and also human H5N1 cases <a href="#pone.0001665-WHO.3">[18]</a>.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5"></a><p>Following the first dose of the vaccine a neutralising response against the subclades 2.2 and 2.3 was evidenced in 35%-45% of subjects. It has been estimated that a pandemic vaccine that provides even partial cross-protection (about 30%) could have substantial impact on attack rates <a href="#pone.0001665-Germann1">[26]</a>, <a href="#pone.0001665-Ferguson1">[27]</a>. Thus in a critical situation where there is not sufficient time or supply of vaccine to administer a second dose, even one dose of the vaccine may help to reduce transmission of the pandemic virus. A high level of cross-immunity (75%–85%) against all three subclades was evident following the second dose. Furthermore we provide evidence that this cross-clade immunity is long-lived as it could still be detected in the majority of subjects at six months following vaccination. The neutralising antibody titres against A/Vietnam/1194/04 homologous virus follow the same trend as the cross-reactive antibody titres against clade 2 viruses (data not shown, manuscript under preparation). Humoral immunity for influenza vaccines has conventionally been assessed by HAI. Our previous experience with A/Indonesia/5/2005 H5N1 strain has shown that cross-reactivity is stronger when assessed by the more sensitive neutralisation assay <a href="#pone.0001665-LerouxRoels1">[23]</a> which provides an evaluation of the vaccine activity against both the HA and the NA antigens and consequently, gives a more comprehensive evaluation of the biological activity of the vaccine. This was confirmed in this present study for the recombinant A/turkey/Turkey/1/2005 and A/Anhui/1/2005 strains.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6"></a><p>A recent pre-clinical study provides further evidence that vaccination with H5 and N1 antigens from one clade can induce a broadly protective immune response against wild type viruses from another clade <a href="#pone.0001665-Suguitan1">[28]</a>. Suguitan and colleagues showed that vaccines developed from attenuated strains containing H5 and N1 components from 1997 clade 3, 2003 clade 1 or 2004 clade 1 isolates protected mice from lethal challenge with both homologous and heterologous wild type viruses including more recent 2005 clade 1 and clade 2 viruses <a href="#pone.0001665-Suguitan1">[28]</a>. Similar data were generated for protection against pulmonary replication following challenge with these different strains in vaccinated mice and ferrets. The authors suggested that the high level of protection afforded by vaccination with the 1997 clade 3 vaccine against challenge with the clade 1 and clade 2 H5N1 viruses isolated over a span of 8 years, indicates that the H5N1 viruses are evolving to infect different birds, and not predominantly to evade antibodies as they do in humans <a href="#pone.0001665-Suguitan1">[28]</a>. Earlier evidence that an avian influenza vaccine could exhibit cross-immunity came from a study where a surface-antigen vaccine based on the antigenically related H5N3 influenza virus (influenza A/duck/Singapore/97) and adjuvanted with MF59 induced cross-reactive antibodies against H5N1 <a href="#pone.0001665-Stephenson2">[29]</a>. Whereas we did not observe any cross-reactive response following administration of two doses of non-adjuvanted vaccine, these authors did measure some degree of cross-reactivity after three doses of non-adjuvanted vaccine.</p>
<a id="article1.body1.sec4.p7" name="article1.body1.sec4.p7"></a><p>We have previously demonstrated the significant antigen dose-sparing effect of including an oil-in-water emulsion based adjuvant system in the candidate vaccine formulation <a href="#pone.0001665-LerouxRoels1">[23]</a>. This is now re-enforced by the results of this present study which confirm that the adjuvant enhances the effectiveness of a low antigen dose in broadening the immune response. Baras et al <a href="#pone.0001665-Baras1">[30]</a> recently documented in a stringent preclinical model that the AS adjuvanted candidate vaccine described in the present paper provides protection against cross-clade heterologous challenge in ferrets. The availability of H5N1 vaccines that can elicit a broad cross-protective immunity against different currently circulating H5N1 viruses, including newly emerged strains, is a pre-requisite for the development of a successful pre-pandemic vaccination strategy. Deployment of such vaccines for pre-emptive vaccination could play a key role in pandemic mitigation during the several months that it would take to produce an H5N1 vaccine exactly matched to a pandemic strain.</p>
</div>

<div id="section5" class="section"><a id="s5" name="s5" toc="s5" title="Supporting Information"></a><h3>Supporting Information</h3><div class="figshare_widget" doi="10.1371/journal.pone.0001665"></div><a name="pone.0001665.s001" id="pone.0001665.s001"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0001665.s001">Checklist S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material1.caption1.p1" name="article1.body1.sec5.supplementary-material1.caption1.p1"></a><p class="preSiDOI">CONSORT Checklist</p>
<p class="siDoi">doi:10.1371/journal.pone.0001665.s001</p><a id="article1.body1.sec5.supplementary-material1.caption1.p2" name="article1.body1.sec5.supplementary-material1.caption1.p2"></a><p class="postSiDOI">(0.13 MB PDF)</p>
<a name="pone.0001665.s002" id="pone.0001665.s002"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0001665.s002">Flowchart S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material2.caption1.p1" name="article1.body1.sec5.supplementary-material2.caption1.p1"></a><p class="preSiDOI">CONSORT Flowchart</p>
<p class="siDoi">doi:10.1371/journal.pone.0001665.s002</p><a id="article1.body1.sec5.supplementary-material2.caption1.p2" name="article1.body1.sec5.supplementary-material2.caption1.p2"></a><p class="postSiDOI">(0.11 MB PDF)</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>We are grateful to the National Institute for Biological Standards and Control (NIBSC, Potters Bar, UK) for providing the vaccine virus strain, the A/turkey/Turkey/1/2005 strain and reference standards and also to the Centers for Disease Control and Prevention (CDC, Atlanta, USA) for supplying the A/Indonesia/5/2005 and A/Anhui/1/2005 strains. The authors are indebted to the participating clinicians, nurses and laboratory technicians at the study site and the sponsor's project staff for their support and contributions throughout the study. We also want to thank the study volunteers. We would like to thank Ute Förster, Simone Kühn, Sebastian Richter, Kitty Robert, Sven Schaaf, Antje Weidensdorfer and Anne Wendlandt for their excellent, sedulous immunological laboratory work. Finally we would like to thank Miriam Hynes (independent, UK) for her assistance in preparing the manuscript and Isabelle Camby (XPePharma SA, Belgium) for coordination.</p>
<a id="article1.back1.ack1.p2" name="article1.back1.ack1.p2"></a><p>This study was supported by GlaxoSmithKline (GSK) Biologicals, Rixensart, Belgium.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: EH GL IL RB PG MD. Performed the experiments: RB PG. Analyzed the data: EH GL IL RB PG MD. Contributed reagents/materials/analysis tools: EH GL IL RB PG. Wrote the paper: EH GL IL RB PG MD.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0001665-WHO.1" id="pone.0001665-WHO.1"></a>  WHO. Avian influenza: assessing the pandemic threat. <a href="http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/en/index.html">http://www.who.int/csr/disease/influenza​/WHO_CDS_2005_29/en/index.html</a>. Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">2.
              </span><a name="pone.0001665-Stephenson1" id="pone.0001665-Stephenson1"></a>Stephenson I, Gust I, Kieny MP, Pervikov Y (2006) Development and evaluation of pandemic influenza vaccines. Lancet Infect Dis  6: 71–72.  <ul class="find" data-citedArticleID="1061972" data-doi="10.1016/s1473-3099(06)70364-4"><li><a href="http://dx.doi.org/10.1016/s1473-3099(06)70364-4" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Development+and+evaluation+of+pandemic+influenza+vaccines." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Development+and+evaluation+of+pandemic+influenza+vaccines.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0001665-Poland1" id="pone.0001665-Poland1"></a>Poland GA (2006) Vaccines against Avian Influenza—A Race against Time. N Engl J Med  354: 1411–1413.  <ul class="find" data-citedArticleID="1061966" data-doi="10.1056/nejme068047"><li><a href="http://dx.doi.org/10.1056/nejme068047" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Vaccines+against+Avian+Influenza%E2%80%94A+Race+against+Time." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Vaccines+against+Avian+Influenza%E2%80%94A+Race+against+Time.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0001665-Shortridge1" id="pone.0001665-Shortridge1"></a>Shortridge KF (2006) Influenza pandemic preparedness: gauging from EU plans. Lancet  367: 1374–1375.  <ul class="find" data-citedArticleID="1061970" data-doi="10.1016/s0140-6736(06)68512-7"><li><a href="http://dx.doi.org/10.1016/s0140-6736(06)68512-7" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Influenza+pandemic+preparedness%3A+gauging+from+EU+plans." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Influenza+pandemic+preparedness%3A+gauging+from+EU+plans.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0001665-MounierJack1" id="pone.0001665-MounierJack1"></a>Mounier-Jack S, Coker RJ (2006) How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet  367: 1405–1411.  <ul class="find" data-citedArticleID="1061962" data-doi="10.1016/s0140-6736(06)68511-5"><li><a href="http://dx.doi.org/10.1016/s0140-6736(06)68511-5" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=How+prepared+is+Europe+for+pandemic+influenza%3F+Analysis+of+national+plans." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22How+prepared+is+Europe+for+pandemic+influenza%3F+Analysis+of+national+plans.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0001665-Sambhara1" id="pone.0001665-Sambhara1"></a>Sambhara S, Poland GA (2006) Avian influenza vaccines: what's all the flap? Lancet  367: 1636–1638.  <ul class="find" data-citedArticleID="1061968" data-doi="10.1016/s0140-6736(06)68657-1"><li><a href="http://dx.doi.org/10.1016/s0140-6736(06)68657-1" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Avian+influenza+vaccines%3A+what%27s+all+the+flap%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Avian+influenza+vaccines%3A+what%27s+all+the+flap%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0001665-Peiris1" id="pone.0001665-Peiris1"></a>Peiris MJS, de Jong MD, Guan Y (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev  20: 243–267.  <ul class="find" data-citedArticleID="1061964" data-doi="10.1128/cmr.00037-06"><li><a href="http://dx.doi.org/10.1128/cmr.00037-06" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Avian+influenza+virus+%28H5N1%29%3A+a+threat+to+human+health." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Avian+influenza+virus+%28H5N1%29%3A+a+threat+to+human+health.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0001665-Yuen1" id="pone.0001665-Yuen1"></a>Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, et al.  (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet  351: 467–471.  <ul class="find" data-citedArticleID="1061998" data-doi="10.1016/s0140-6736(98)01182-9"><li><a href="http://dx.doi.org/10.1016/s0140-6736(98)01182-9" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Clinical+features+and+rapid+viral+diagnosis+of+human+disease+associated+with+avian+influenza+A+H5N1+virus." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Clinical+features+and+rapid+viral+diagnosis+of+human+disease+associated+with+avian+influenza+A+H5N1+virus.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0001665-Claas1" id="pone.0001665-Claas1"></a>Claas ECJ, Osterhaus ADME, van Beek R, De Jong JC, Rimmelzwaan , et al.  (1998) Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351: 472–477. Erratum in: Lancet 1998 Apr 25;  351(9111): 1292.  <ul class="find" data-citedArticleID="1061944" data-doi="10.1016/s0140-6736(97)11212-0"><li><a href="http://dx.doi.org/10.1016/s0140-6736(97)11212-0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+influenza+A+H5N1+virus+related+to+a+highly+pathogenic+avian+influenza+virus.+Lancet+351%3A+472%E2%80%93477." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+influenza+A+H5N1+virus+related+to+a+highly+pathogenic+avian+influenza+virus.+Lancet+351%3A+472%E2%80%93477.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0001665-Subbarao1" id="pone.0001665-Subbarao1"></a>Subbarao K, Klimov A, Katz J, Regnery H, Lim W, et al.  (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science  279: 393–396.  <ul class="find" data-citedArticleID="1061976" data-doi="10.1126/science.279.5349.393"><li><a href="http://dx.doi.org/10.1126/science.279.5349.393" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Characterization+of+an+avian+influenza+A+%28H5N1%29+virus+isolated+from+a+child+with+a+fatal+respiratory+illness." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Characterization+of+an+avian+influenza+A+%28H5N1%29+virus+isolated+from+a+child+with+a+fatal+respiratory+illness.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0001665-WHO.2" id="pone.0001665-WHO.2"></a>  WHO. Cumulative number of confirmed cases of avian influenza A/(H5N1) reported to WHO. <a href="http://www.who.int/csr/disease/avian_influenza/country/cases_table_2007_10_02/en/index.html">http://www.who.int/csr/disease/avian_inf​luenza/country/cases_table_2007_10_02/en​/index.html</a>. Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">12.
              </span><a name="pone.0001665-Ungchusak1" id="pone.0001665-Ungchusak1"></a>Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, et al.  (2005) Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med  352: 333–340.  <ul class="find" data-citedArticleID="1061986" data-doi="10.1056/nejmoa044021"><li><a href="http://dx.doi.org/10.1056/nejmoa044021" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Probable+person-to-person+transmission+of+avian+influenza+A+%28H5N1%29." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Probable+person-to-person+transmission+of+avian+influenza+A+%28H5N1%29.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0001665-Kandun1" id="pone.0001665-Kandun1"></a>Kandun IN, Wibisono H, Sedyaningsih ER, Yusharmen , Hadisoedarsuno W, et al.  (2006) Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med  355: 2186–2194.  <ul class="find" data-citedArticleID="1061956" data-doi="10.1056/nejmoa060930"><li><a href="http://dx.doi.org/10.1056/nejmoa060930" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Three+Indonesian+clusters+of+H5N1+virus+infection+in+2005." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Three+Indonesian+clusters+of+H5N1+virus+infection+in+2005.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0001665-WHO1" id="pone.0001665-WHO1"></a>  WHO Global pandemic influenza action plan to increase vaccine supply WHO/IVB/06.13. WHO September 2006. <a href="http://www.who.int/immunization/documents/WHO_IVB_06.13/en/index.html">http://www.who.int/immunization/document​s/WHO_IVB_06.13/en/index.html</a>. Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">15.
              </span><a name="pone.0001665-European1" id="pone.0001665-European1"></a>  European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products, (April 5, 2004).  <ul class="find-nolinks"></ul></li><li><span class="label">16.
              </span><a name="pone.0001665-US1" id="pone.0001665-US1"></a>  US Food and Drug Administration. Guidance on Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. <a href="http://www.fda.gov/cber/gdlns/panfluvac.htm">http://www.fda.gov/cber/gdlns/panfluvac.​htm</a>. Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">17.
              </span><a name="pone.0001665-Webby1" id="pone.0001665-Webby1"></a>Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, et al.  (2004) Responsiveness to use of reverse genetics for rapid development of influenza vaccines. Lancet  363: 1099–1103.  <ul class="find" data-citedArticleID="1061996" data-doi="10.1016/s0140-6736(04)15892-3"><li><a href="http://dx.doi.org/10.1016/s0140-6736(04)15892-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Responsiveness+to+use+of+reverse+genetics+for+rapid+development+of+influenza+vaccines." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Responsiveness+to+use+of+reverse+genetics+for+rapid+development+of+influenza+vaccines.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0001665-WHO.3" id="pone.0001665-WHO.3"></a>  WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. March 2007 <a href="http://www.who.int/csr/disease/avian_influenza/guidelines/recommendationvaccine.pdf">http://www.who.int/csr/disease/avian_inf​luenza/guidelines/recommendationvaccine.​pdf</a>. Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">19.
              </span><a name="pone.0001665-Treanor1" id="pone.0001665-Treanor1"></a>Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med  354: 1343–1351.  <ul class="find" data-citedArticleID="1061980" data-doi="10.1056/nejmoa055778"><li><a href="http://dx.doi.org/10.1056/nejmoa055778" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Safety+and+immunogenicity+of+an+inactivated+subvirion+influenza+A+%28H5N1%29+vaccine." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Safety+and+immunogenicity+of+an+inactivated+subvirion+influenza+A+%28H5N1%29+vaccine.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0001665-Bresson1" id="pone.0001665-Bresson1"></a>Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, et al.  (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet  367: 1657–1664.  <ul class="find" data-citedArticleID="1061942" data-doi="10.1016/s0140-6736(06)68656-x"><li><a href="http://dx.doi.org/10.1016/s0140-6736(06)68656-x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Safety+and+immunogenicity+of+an+inactivated+split-virion+influenza+A%2FVietnam%2F1194%2F2004+%28H5N1%29+vaccine%3A+phase+I+randomised+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Safety+and+immunogenicity+of+an+inactivated+split-virion+influenza+A%2FVietnam%2F1194%2F2004+%28H5N1%29+vaccine%3A+phase+I+randomised+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0001665-Lin1" id="pone.0001665-Lin1"></a>Lin J, Zhang J, Dong X, Fang H, Chen J, et al.  (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet  368: 991–997.  <ul class="find" data-citedArticleID="1061960" data-doi="10.1016/s0140-6736(06)69294-5"><li><a href="http://dx.doi.org/10.1016/s0140-6736(06)69294-5" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Safety+and+immunogenicity+of+an+inactivated+adjuvanted+whole-virion+influenza+A+%28H5N1%29+vaccine%3A+a+phase+I+randomised+controlled+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Safety+and+immunogenicity+of+an+inactivated+adjuvanted+whole-virion+influenza+A+%28H5N1%29+vaccine%3A+a+phase+I+randomised+controlled+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0001665-Hehme1" id="pone.0001665-Hehme1"></a>Hehme N, Kuhn A, Mueller M, Preusche A, Riemer N, Schussmann KM, Tuerk G, Neumeier E, Borkowski A, Sänger RWhole virus alum-adjuvanted pandemic vaccine: Safety and immunogenicity data on a vaccine formulated with H5N1. International Conference on Influenza Vaccines for the World–IVW 2006 18–20 October, 2006, Vienna, Austria  <ul class="find" data-citedArticleID="1061954"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Whole+virus+alum-adjuvanted+pandemic+vaccine%3A+Safety+and+immunogenicity+data+on+a+vaccine+formulated+with+H5N1.+International+Conference+on+Influenza+Vaccines+for+the+World%3FIVW+2006+18%3F20+October%2C+2006%2C+Vienna%2C+Austria&amp;auth=&amp;atitle=Whole+virus+alum-adjuvanted+pandemic+vaccine%3A+Safety+and+immunogenicity+data+on+a+vaccine+formulated+with+H5N1.+International+Conference+on+Influenza+Vaccines+for+the+World%3FIVW+2006+18%3F20+October%2C+2006%2C+Vienna%2C+Austria" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Whole+virus+alum-adjuvanted+pandemic+vaccine%3A+Safety+and+immunogenicity+data+on+a+vaccine+formulated+with+H5N1.+International+Conference+on+Influenza+Vaccines+for+the+World%E2%80%93IVW+2006+18%E2%80%9320+October%2C+2006%2C+Vienna%2C+Austria" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Whole+virus+alum-adjuvanted+pandemic+vaccine%3A+Safety+and+immunogenicity+data+on+a+vaccine+formulated+with+H5N1.+International+Conference+on+Influenza+Vaccines+for+the+World%E2%80%93IVW+2006+18%E2%80%9320+October%2C+2006%2C+Vienna%2C+Austria%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0001665-LerouxRoels1" id="pone.0001665-LerouxRoels1"></a>Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, et al.  (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet  370: 580–589.  <ul class="find" data-citedArticleID="1061958" data-doi="10.1016/s0140-6736(07)61297-5"><li><a href="http://dx.doi.org/10.1016/s0140-6736(07)61297-5" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antigen+sparing+and+cross-reactive+immunity+with+an+adjuvanted+rH5N1+prototype+pandemic+influenza+vaccine%3A+a+randomised+controlled+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antigen+sparing+and+cross-reactive+immunity+with+an+adjuvanted+rH5N1+prototype+pandemic+influenza+vaccine%3A+a+randomised+controlled+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0001665-European2" id="pone.0001665-European2"></a>  European Committee for Proprietary Medicinal Products. Committee for medicinal products for human use summary of positive opinion for DARONRIX Common Name: A/Viet Nam/1194/2004 (H5N1) whole virus inactivated antigen. (EMEA/CHMP/495962/2006) <a href="http://www.emea.europa.eu/humandocs/Humans/EPAR/daronrix/daronrix.htm">http://www.emea.europa.eu/humandocs/Huma​ns/EPAR/daronrix/daronrix.htm</a> Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">25.
              </span><a name="pone.0001665-US2" id="pone.0001665-US2"></a>  US Food and Drug Administration. First ‘bird flu’ vaccine for humans approved. 2007. <a href="http://www.fda.gov/consumer/updates/birdflu043007.html">http://www.fda.gov/consumer/updates/bird​flu043007.html</a>. Accessed January 28th, 2008.  <ul class="find-nolinks"></ul></li><li><span class="label">26.
              </span><a name="pone.0001665-Germann1" id="pone.0001665-Germann1"></a>Germann TC, Kadau K, Longini IM Jr, Macken CA (2006) Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A  103: 5935–5940.  <ul class="find" data-citedArticleID="1061952" data-doi="10.1073/pnas.0601266103"><li><a href="http://dx.doi.org/10.1073/pnas.0601266103" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Mitigation+strategies+for+pandemic+influenza+in+the+United+States." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Mitigation+strategies+for+pandemic+influenza+in+the+United+States.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0001665-Ferguson1" id="pone.0001665-Ferguson1"></a>Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS (2006) Strategies for mitigating an influenza pandemic. Nature  442: 448–452.  <ul class="find" data-citedArticleID="1061950" data-doi="10.1038/nature04795"><li><a href="http://dx.doi.org/10.1038/nature04795" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Strategies+for+mitigating+an+influenza+pandemic." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Strategies+for+mitigating+an+influenza+pandemic.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0001665-Suguitan1" id="pone.0001665-Suguitan1"></a>Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, et al.  (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med  3(9): e360.  doi:10.1371/journal.pmed.0030360.  <ul class="find" data-citedArticleID="1061978" data-doi="10.1371/journal.pmed.0030360"><li><a href="http://dx.doi.org/10.1371/journal.pmed.0030360" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Live%2C+attenuated+influenza+A+H5N1+candidate+vaccines+provide+broad+cross-protection+in+mice+and+ferrets." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Live%2C+attenuated+influenza+A+H5N1+candidate+vaccines+provide+broad+cross-protection+in+mice+and+ferrets.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0001665-Stephenson2" id="pone.0001665-Stephenson2"></a>Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, et al.  (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis  191: 1210–1215.  <ul class="find" data-citedArticleID="1061974" data-doi="10.1086/428948"><li><a href="http://dx.doi.org/10.1086/428948" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cross-reactivity+to+highly+pathogenic+avian+influenza+H5N1+viruses+after+vaccination+with+nonadjuvanted+and+MF59-adjuvanted+influenza+A%2FDuck%2FSingapore%2F97+%28H5N3%29+vaccine%3A+a+potential+priming+strategy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cross-reactivity+to+highly+pathogenic+avian+influenza+H5N1+viruses+after+vaccination+with+nonadjuvanted+and+MF59-adjuvanted+influenza+A%2FDuck%2FSingapore%2F97+%28H5N3%29+vaccine%3A+a+potential+priming+strategy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0001665-Baras1" id="pone.0001665-Baras1"></a>Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al.  (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. Plos One  3(1): e1401.  doi:10.1371/journal.pone.0001401.  <ul class="find" data-citedArticleID="1061940" data-doi="10.1371/journal.pone.0001401"><li><a href="http://dx.doi.org/10.1371/journal.pone.0001401" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cross-protection+against+lethal+H5N1+challenge+in+ferrets+with+an+adjuvanted+pandemic+influenza+vaccine." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cross-protection+against+lethal+H5N1+challenge+in+ferrets+with+an+adjuvanted+pandemic+influenza+vaccine.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.XML" value="57427"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.PDF" value="151102"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g001.PNG_L" value="175113"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g001.PNG_M" value="44827"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g001.PNG_S" value="8709"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g001.TIF" value="316914"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g001.PNG_I" value="17636"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g002.PNG_L" value="155223"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g002.PNG_M" value="44095"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g002.PNG_S" value="8355"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g002.TIF" value="277296"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.g002.PNG_I" value="16250"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.s001.PDF" value="127304"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001665.s002.PDF" value="111963"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001665&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001665" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001665&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0001665&volume=&issue=&title=Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine&author_name=Isabel%20Leroux-Roels%2C%20Roger%20Bernhard%2C%20Pascal%20G%C3%A9rard%2C%20Mamadou%20Dram%C3%A9%2C%20Emmanuel%20Hanon%2C%20Geert%20Leroux-Roels&start_page=1&end_page=5" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0001665" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665&amp;t=Broad%20Clade%202%20Cross-Reactive%20Immunity%20Induced%20by%20an%20Adjuvanted%20Clade%201%20rH5N1%20Pandemic%20Influenza%20Vaccine" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665&title=Broad%20Clade%202%20Cross-Reactive%20Immunity%20Induced%20by%20an%20Adjuvanted%20Clade%201%20rH5N1%20Pandemic%20Influenza%20Vaccine&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665&amp;title=Broad%20Clade%202%20Cross-Reactive%20Immunity%20Induced%20by%20an%20Adjuvanted%20Clade%201%20rH5N1%20Pandemic%20Influenza%20Vaccine" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0001665&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0001665';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Broad%20Clade%202%20Cross-Reactive%20Immunity%20Induced%20by%20an%20Adjuvanted%20Clade%201%20rH5N1%20Pandemic%20Influenza%20Vaccine http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001665" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0001665" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">























          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Antibodies%22" title="Search for articles in the subject area:'Antibodies'"><div class="flagText">Antibodies</div></a>
              <div data-categoryid="47389" data-articleid="26156"
                   data-categoryname="Antibodies"
                   class="flagImage" title="Flag 'Antibodies' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Antigens%22" title="Search for articles in the subject area:'Antigens'"><div class="flagText">Antigens</div></a>
              <div data-categoryid="32115" data-articleid="26156"
                   data-categoryname="Antigens"
                   class="flagImage" title="Flag 'Antigens' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22H5N1%22" title="Search for articles in the subject area:'H5N1'"><div class="flagText">H5N1</div></a>
              <div data-categoryid="47163" data-articleid="26156"
                   data-categoryname="H5N1"
                   class="flagImage" title="Flag 'H5N1' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Immunity%22" title="Search for articles in the subject area:'Immunity'"><div class="flagText">Immunity</div></a>
              <div data-categoryid="34745" data-articleid="26156"
                   data-categoryname="Immunity"
                   class="flagImage" title="Flag 'Immunity' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Recombinant+vaccines%22" title="Search for articles in the subject area:'Recombinant vaccines'"><div class="flagText">Recombinant vaccines</div></a>
              <div data-categoryid="34023" data-articleid="26156"
                   data-categoryname="Recombinant vaccines"
                   class="flagImage" title="Flag 'Recombinant vaccines' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Vaccination+and+immunization%22" title="Search for articles in the subject area:'Vaccination and immunization'"><div class="flagText">Vaccination and immunization</div></a>
              <div data-categoryid="31857" data-articleid="26156"
                   data-categoryname="Vaccination and immunization"
                   class="flagImage" title="Flag 'Vaccination and immunization' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Vaccines%22" title="Search for articles in the subject area:'Vaccines'"><div class="flagText">Vaccines</div></a>
              <div data-categoryid="31861" data-articleid="26156"
                   data-categoryname="Vaccines"
                   class="flagImage" title="Flag 'Vaccines' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Viral+vaccines%22" title="Search for articles in the subject area:'Viral vaccines'"><div class="flagText">Viral vaccines</div></a>
              <div data-categoryid="19407" data-articleid="26156"
                   data-categoryname="Viral vaccines"
                   class="flagImage" title="Flag 'Viral vaccines' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=1392'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=6492'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=5793&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>

<div class="block sidebar-comments">
    <div class="header">
        <h3>Comments</h3>
    </div>
      <p><a href="/annotation/listThread.action?root=11237">Referee comments: Referee 1</a><br>Posted by PLoS_ONE_Group</p>
</div>

</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
